BACK

Benj Garrett

Benj Garrett

Managing Director

New York Office  |  benj.garrett@torreya.com   |   212.257.5807

Benj Garrett, a Managing Director at Torreya, specializes in the execution of international strategic M&A transactions in the biotechnology, pharmaceutical, and generic sectors. Since joining Torreya in 2008, Benj has participated in numerous strategic transactions including several with Japanese clients.

Benj graduated summa cum laude from NYU’s Stern School of Business, with a B.S. in finance and statistics.

He is a registered representative with Financial West Group.

Selected Transactions

Sawai
Acquisition of
generics business of
Upsher-Smith
$1.05 billion
June 2017
Concordia International Corp.
Acquisition of
Donnatal® from
Revive Pharmaceuticals
$328 million
May 2014
SciDose
Partial sale of royalty
and milestones
Undisclosed
$40 million
September 2016
Eisai
Sale of Akarx to
PBM Capital Group
Undisclosed
March 2016
Plexcera Therapeutics
Sale and contribution of orphan disease asset to
Roivant Sciences
Undisclosed
May 2016
Sandoz
Sale of
generics portfolio to
FosunPharma
$18 million
August 2017
XOMA
Sale of royalties to
Healthcare Royalty Partners
$22 million
December 2016
Academic Investor
Sale of
phase II enzyme replacement royalty
Undisclosed
Undisclosed
August 2016
Sandoz
Sale of
Zonalon® to
Renaissance Pharma
Undisclosed
March 2015
Flamel Technologies
Sale of Pessac plant to
Recipharm AB
Up to €22 million
November 2014
Sandoz
Divestiture of
certain abbreviated
new drug applications to
IDT Australia
Up to $18 million
October 2014
Teva
Sale of 31 abbreviated
new drug applications to
ANI Pharmaceuticals
$12.5 million +
profit share
December 2013
Pinnacle Biologics
Sale to
Concordia Healthcare
Undisclosed
December 2013
Correvio
Sale to
Cardiome
19.9% of shares +
$12 million
November 2013
Shionogi
Sale of Naprelan® to
Alvogen
Undisclosed
November 2013
Shionogi
Divestiture of three pediatric drugs to
Concordia Pharmaceuticals
$28.7 million
May 2013
GTx
Sale of Fareston® to
Prostrakan/Kyowa Hakko Kirin
$21.7 million
October 2012
Shionogi
Divestiture of
Cuvposa® to
Merz
Undisclosed
August 2012
Quinnova
Sale of dermatology specialty pharma
business to
Amneal
Undisclosed
December 2010
Three Rivers Pharma
Sale to
Kadmon
$100+ million
October 2010
GTCR
Advisor in the acquisition of six products from
UCB
Undisclosed
July 2010
Columbia Labs
Sale of
Crinone® & Prochieve® product lines and
shares to
Watson
$92.5 million with
$47 million upfront
July 2010
Shareholder Group
Advisor to Genentech
major shareholder
in sale to
Roche
$46 billion
March 2009